Just over a century ago, on the third of October 1910, Johann Feigl, a 59-year-old day labourer from Munich, died after contracting pneumonia, after three years of suffering from a kind of dementia similar to that of Auguste Deter, whose case was reported at a psychiatrists' conference in November 1906. For the first time in history, the cause of death was recorded as Alzheimer's disease, after Alois Alzheimer , who had four years earlier described his investigations of Auguste Deter's brain autopsy to an audience that failed to recognise the dawn of a new era.
Johann Feigl was to be the first of many millions. With the drastic increase in life expectancy in the western world throughout the 20 th century, Alois Alzheimer's discovery rapidly gained importance and became one of the most serious medical problems of our time. In the UK alone there are currently 800,000 people with dementia, and this number is projected to double within 40 years. Most of them will have the type of dementia that Alois Alzheimer described, although, at the moment, the post-mortem is the only reliable way to find out. In the autopsies of his patients Feigl and Deter, Alzheimer had observed the deposition of plaques between neurons, and the loss of brain cells leaving large gaps and making the brain look shrivelled.
Later biochemical analyses showed that these plaques contain fibrils of a characteristic structure formed by a peptide called amyloid b, or Ab for short. Similar fibrils made from other peptides were also discovered in Parkinson's disease, type 2 diabetes, and the prion diseases. In the 1990s, researchers found that many proteins and peptides, including some with no disease association at all, were able to form these structures, and 'protein misfolding' became a major field of investigation.
Progress in the quest to understand how and why these fibrils form, whether and how they cause disease (or whether they are just a by-product of disease processes), and how the amyloid-associated diseases can be cured or even averted may appear slow compared to the rapid increase in disease burden. However, significant advances have been made in the last decade, and a recent series of discoveries offers hope that the pace of progress is now increasing significantly.
Folding and misfolding
After the discovery that many different proteins and peptides can form Features amyloid fibrils, the prevailing view was that their formation must start from a largely unfolded state, close to the random coil, seeing that this was the only conformational state that the very diverse proteins all had in common. In recent years, however, attention turned to intermediates much closer to the native state (Nat. Chem. Biol. (2009) 5, 15-22) , which apparently can still turn into amyloid, suggesting that there are many different paths leading to the fibrillar structure.
Lewis Kay and colleagues at the University of Toronto, in collaboration with Michele Vendruscolo and others in Cambridge, have now pinned down such an intermediate using a recently developed, highly sophisticated NMR approach, the Carr-Purcell-MeiboomGill (CPMG) relaxation dispersion After a century of explosive growth in the number of people affected by Alzheimer's disease, there is now growing hope that the dementia can be better understood, recognised earlier, and ultimately cured or even prevented. Michael Gross reports. Why didn't the intermediate aggregate out as amyloid in their previous experiment? The reason is likely to be the very low populationas only 2% of the molecules adopt this structure at a given time, they have a much reduced probability of bumping into other aggregation-prone molecules and reacting with them. While the molecular details of this case may or may not be generalisable to other amyloid-forming proteins, it is noteworthy and likely to be of general importance that a nearnative intermediate can still be highly amyloidogenic and is only prevented from forming amyloid fibrils by being highly diluted amongst more stable forms of the protein.
Understanding amyloid and Alzheimer's disease
"This is an exciting approach to studying protein folding reactions, because it allows us to catch a fleeting glimpse of proteins at their most vulnerable," says biophysicist Cait McPhee from the University of Edinburgh. "And it's surprising and perhaps a little disturbing that such a small, apparently insignificant change is sufficient to tip the balance between a well-behaved protein and one that is prone to aggregation. Up until now we've assumed some fairly drastic structural rearrangements were required -but it now appears that's not the case."
But will it help at the medical front? Chris Dobson from the University of Cambridge is optimistic: "The development of an array of increasingly sophisticated biophysical techniques, such as that used by Lewis Kay and his colleagues, is now proceeding very rapidly and is transforming our ability to define in exquisite detail the molecular steps involved in the process of amyloid formation by specific proteins," he commented. "With this information it is becoming possible not just to understand the molecular origins of misfolding diseases but to use this information for the rational design of therapeutic strategies to combat these devastating diseases."
Cause or symptom?
A long-running debate in the field concerns the question whether the amyloid fibrils are ultimately the cause of the brain damage in Alzheimer's disease or whether they are just a side-effect produced by as yet unresolved underlying mechanisms that lead to neuronal death. In recent years, attention has shifted away from the full-length fibrils and towards smaller units, so called amyloid oligomers, which have been found to be more cytotoxic than the mature fibres. They may only contain half a dozen protein molecules, but they do show specific structural elements distinct from both the protein monomers and the full amyloid fibrils. There are, for instance, antibodies that specifically recognise the oligomers, but neither the monomers nor the fibrils.
The group of David Eisenberg at the University of California at Los Angeles has recently reported the crystal structure of such a cytotoxic amyloid oligomer, derived from the eye lens chaperone aB crystallin (Science (2012), 335, 1228-1231). The structural unit is a small barrel of six antiparallel b strands, which they called a cylindrin. The antiparallel b sheets in the barrel are staggered with respect to the neighbouring sheets ('out of register') while the structures of full-length fibrils show neatly lined up beta sheets ('in register') all the way through. Thus there is no quick and easy way of converting the cylindrin structure into the fibril structure, and many hydrogen bonds would have to be broken to achieve this conversion. Eisenberg and colleagues conclude that the cylindrin is probably not an intermediate on the pathway leading to full-length fibrils.
The researchers also admit that their "cylindrin may represent one of many possible assemblies of cylindrin-like structures." Thus, the number of peptides per oligomer and the dislocation between neighbouring strands may be variable and produce a wide variety of structurally different complexes. Which of these are medically relevant remains to be explored.
In another recent development, David Klenerman's and Chris Dobson's groups in Cambridge have shown that misfolding results in a wide distribution of toxic oligomers, using single-molecule techniques that enable the researchers to observe and begin to characterise the oligomers (Nat. Struct. Mol. Biol. (2012) 19, 79-83) . "Our paper also shows that the extracellular chaperone clusterin sequesters these oligomers and hence provides important clues as to how our natural defences function," Dobson told Current Biology.
Diagnosis and therapy
Initially, the hallmark brain changes distinguishing Alzheimer's disease from other kinds of dementia could only be detected post mortem in a brain autopsy. Brain imaging methods like magnetic resonance imaging (MRI), positron emission tomography (PET) and single photon emission computed tomography (SPECT) have provided some help, but experts still estimate that one in five patients diagnosed with Alzheimer's while they were alive failed to display the characteristic symptoms on autopsy.
Only in April this year did the US Food and Drug Administration (FDA) approve the first substance for a diagnostic test that can detect plaques in the living brain. The test developed by the company Eli Lilly is based on a radioactively (fluorine-19) labelled compound called florbetapir (product name: Amyvid), which binds to amyloid plaques and can be detected in PET scans.
Making a diagnosis based on these scans is far from easy, however. A previous application from Eli Lilly was turned down by the FDA on the grounds that the training the company provided for the interpretation of the scans was insufficient. Still, even a specially trained doctor may get the result wrong, and the best diagnoses were obtained in a study where each scan was read by five people and the majority vote decided the verdict.
And even with training and controls in place, the company admits in its product information that "a positive Amyvid scan does not establish a diagnosis of Alzheimer's disease, or other cognitive disorder."
Commenting on the announced FDA approval for Amyvid, which failed to translate into a rise in share prices for the company, Matthew Herper of Forbes magazine wrote that, while the method has little benefit for people actually suffering from Alzheimer's, it is useful to rule out the possibility in those who don't. "If drug companies can screen out patients who are likely not to have Alzheimer's, they are far more likely to be able to show that medicines aimed at Alzheimer's are effective in clinical trials. Having those non-Alzheimer's patients in a study is going to wash out the efficacy of a new drug," Herper writes, concluding: "This really is a clever move by Lilly to make some profit on a research tool."
The other reason why diagnostic tools aren't much use for the patients right now is the fact that there is no therapeutic intervention that actually stops the progress of the disease, let alone restores the healthy brain. All drugs available for Alzheimer's patients so far can alleviate symptoms but can neither stop nor cure the disease. What could a successful therapy look like? A recent study with an animal model offers a glimpse of a better future.
The group of Gary Landreth at the Case Western University at Cleveland (Ohio, US) has recently reported a very promising study showing that a drug that is already approved for other diseases can clear soluble amyloid and plaques and restore cognitive functions in a mouse model of Alzheimer's disease (Science (2012 (Science ( ), 335, 1503 (Science ( -1506 . The miracle compound is betaroxene (Targretin), a substance that can permeate the blood-brain barrier and activates retinoid X receptors (RXRs). These membrane proteins form dimers with other receptors known to upregulate the activity of the apoE gene, resulting in the production of apolipoprotein E. This lipoprotein helps the formation of high density lipoprotein (HDL) particles, which in turn speed up the digestion and clearance of soluble Ab. Mutations in the apoE gene are the most common genetic defect associated with sporadic Alzheimer's, thus activation of the gene is considered to be a promising approach.
Landreth and colleagues found that oral administration of bexarotene resulted in improved clearance of soluble Ab within a few hours, due to enhanced apoE activity. They also found that the area affected by Ab plaques was reduced by half within three days. Most encouragingly, the mice regained cognitive, social, and olfactory abilities they had already lost to the disease. The UK's Alzheimer's Society welcomed the news with cautious enthusiasm: "This exciting study could be the beginning of a journey towards a potential new way to treat Alzheimer's disease," commented Anne Corbett, research manager for the society. She cautioned: "However, this is very early days. People with Alzheimer's should not rush to get this drug, as we need much more research to establish if it has benefits for humans."
More generally, the Alzheimer's Society sees hope in the approach of finding Alzheimer drugs among the substances already approved for other applications. "Investigating the added benefits of existing licensed drugs is an innovative approach in our fight against the condition, and one which Alzheimer's Society is championing through its drug discovery programme. This could see new treatments for dementia being developed much sooner," the statement said.
As more and more people are reaching the age where Alzheimer's disease becomes a dominant health risk, the need for real treatment options is getting more urgent. Alois Alzheimer, however, did not live long enough to get 'his' disease. In December 1915, just a few years after his name became attached to the dementia, he succumbed to complications after contracting an infectious disease aged 51, a fairly normal fate in a bygone world without antibiotics, where only academic psychiatrists knew about Alzheimer's disease.
Michael Gross is a science writer based at Oxford. He can be contacted via his web page at www.michaelgross.co.uk Two years on, the national spotlight seems to have turned away from the Gulf oil spill, but a massive assessment of the environmental impacts is quietly under way. As Cyrus Martin reports, several recent observations, and a study of deepwater coral communities, suggest we may not be out of the woods yet.
Friday April 20 th marked the second anniversary of the US's largest ever oil spill, which began when the Deepwater Horizon oil rig experienced a blowout and explosion while drilling off the coast of Louisiana. Eleven men died in the explosion, which resulted in a gushing wellhead many thousands of feet below the surface that for months frustrated attempts to plug it. When the Macondo well was finally capped, nearly 5 million gallons of 'sweet' crude had been injected into the seawater at great depth, some of it surfacing and infiltrating the coast. At the time, the spill had acute effects on the economies of the Gulf states, as many local fishermen were forced to keep their boats in dock when leaked crude inevitably contaminated their fisheries. And the tourism industry took a big hit as the spill unfortunately coincided with the peak of the season.
Just last month, BP, the operator of the well, agreed in court to pay $7.8 billion in claims to the aggrieved parties -at least 100,000 plaintiffs. And these were just the claims from private individuals; the government itself is likely to extract more in future litigation. For example, a stipulation in the Clean Water Act requires that BP pay a fine based on the amount of oil spilled, fines that are estimated to exceed $3 billion. Ideally, this money would be funnelled back to the Gulf states themselves but legislation introduced in Congress known as the Restore Act has yet to be approved by both houses.
The total amount of money wrung from BP's pockets will depend on an ongoing assessment of the environmental impact in the Gulf stemming from the leak, and the steps needed to repair the damage. This begs the question: what, if anything, has happened to the Gulf coast's ecosystems? Coincidentally, Earth Day follows close on the heels of the spill anniversary, giving even more reason to reassess the environmental impacts.
In the immediate aftermath of the leak, it was clear that the effects of the spill would be far-reaching. Local residents stepped out on their beaches to see their shoreline awash in oil. An initial survey of 4,300 miles of coast found 1,100 miles of oiled shoreline, 220 miles heavily so. As in the case of the Valdez disaster, the plight of the most conspicuous wildlife was center stage. Rescue volunteers and news media, fanning out to assess the impacts of the spill, were confronted with dead or dying waterfowl, and sea turtles greased with petroleum. There was wide speculation that we were reliving Valdez, but on a much larger scale.
Fast forward to today, by contrast, and the Gulf seems to be back in business. Locals and tourists alike flock to the beaches and are by and large greeted by the pristine beauty of the Gulf just as it was. And by all accounts, most of the fisheries are seeing productivity comparable to pre-spill times. But there have been several ominous events in the aftermath of the spill that suggest something sinister may be lurking in the shadows. For one, the beaches aren't quite as immaculate as BP's public relations campaign would indicate. Unsightly tar balls do still wash ashore, and there are many wetlands where, if you use an oar to poke through the marsh grass, a dark sludge is revealed. Perhaps the most portentous sign has been a spate of dolphin beachings up and down the Gulf coast. According to the National Oceanic and Atmospheric Administration (NOAA), 75 dolphins a year on average beach themselves along the Gulf coast, but since February, 2010, the region has witnessed 675 beached dolphins, many of them with low body weight, anemia, hypoglycemia, and liver and lung disease. Many of the dolphins are also infected with the bacterium Brucella, but so far there have been no conclusive links between these symptoms, the pathogen, and the oil spill itself. Further clouding these events, NOAA is reporting that the dolphin beachings started to increase before the Macondo wellhead ever Gulf spill two years out
